INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.

"D. M. Brown: Consultant for and has received research funding from Adverum, Allergan, Chengdu Kanghong Biotechnology, Clearside Biomedical, Genentech/Roche, Heidelberg, Novartis, OHR, Regeneron Pharmaceuticals, Inc., RegenXBio, Santen, and Samsung. He is also a consultant for Bayer, Biotime, Kodiak, Optos, and Senju outside of the submitted work. D. S. Boyer: Consultant for Genentech, Regeneron Pharmaceuticals, Inc., Roche, Bayer, Allergan, Chengdu Kanghong Biotechnology, Clearside Biomedical, Boehringer Ingelheim, Kodiak, Novartis, Adverum, RegenXBio, and Graybug. K. Csaky: Consultant for Genentech, Roche, Allergan, Novartis, and Regeneron Pharmaceuticals, Inc. R. Vitti, L. Perlee, K. W. Chu, and Y. Cheng: Employees of and stockholders in Regeneron Pharmaceuticals, Inc. F. Asmus: Employee of Bayer AG at the time of the study. T. Schmelter: Employee of and stockholder in Bayer AG. O. Zeitz: Consultant and speaker for Allergan, Bayer, Boehringer Ingelheim, and Novartis; a consultant for Omeicos and Oxular; and receives research support from Bayer, Boehringer-Ingelheim, and Novartis. Employment with Bayer ended September 30, 2016. S. Leal: Employee of and stockholder in Bayer Consumer Care AG. J. S. Heier: Consultant for 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Alzheon, Annexon, Apellis, Aprea, Asclepix, Aviceda, Beaver-Visitec, Bionic Vision Technologies, DTx, Eloxx, Galimedix, Genentech, Graybug, Gyroscope, Horizon Therapeutics, iRenix, Iveric, JCyte, Chengdu Kanghong Biotechnology, LensGen, NGM, Notal Vision, Novartis, Ocular Therapeutix, OccuTerra, Oxurion, Palatin, Regeneron Pharmaceuticals, Inc., RegenXBio, Stealth, Thea, Verseon, Vinci, and Voyant and has received research grants from Aerpio, Aldeyra, Apellis, Asclepix, Bayer, Genentech, Graybug, Gyroscope, Hermera, Iveric, Janssen R&D, JCyte, Chengdu Kanghong Biotechnology, Kodiak, Novartis, Regeneron Pharmaceuticals, Inc., RegenXBio, and Stealth."

"The RUBY study was funded by Regeneron Pharmaceuticals, Inc., Tarrytown, New York, and Bayer HealthCare, Berlin, Germany. The sponsors participated in the design and conduct of the study, analysis of the data, and preparation of the manuscript."